Latest Taro Pharm Inds (TARO) Headlines
Caesarstone, Check Point Show Strong Fundamentals
at Investor's Business Daily - Fri Mar 07, 3:13PM CST
Although Chinese stocks have dominated this column in recent sessions, they are not the only game in town for investors looking to gain foreign exposure. A few Israeli firms also offer strong fundamentals and technicals. Caesarstone's (CSTE) top-line...
Ascending Bases Are Rare, But Can Spark Big Gains
at Investor's Business Daily - Fri Feb 21, 1:40PM CST
Sometimes, bullish technical setups aren't hard to see at all. A stock in an uptrend, for example, pauses to catch its breath, moves sideways for a bit and a flat base takes shape. Or a stock corrects 25% to 30% from its 52-week high, then starts to...
Taro Provides Results for December 31, 2013
Business Wire - Mon Feb 10, 4:05PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three months and nine months ended December 31, 2013.
Research and Markets: Agrochemicals and Pesticides Market in Iran: Business Report 2013
Business Wire - Tue Feb 04, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/h3sm5l/agrochemicals_and) has announced the addition of the "Agrochemicals and Pesticides Market in Iran: Business Report 2013" report to their offering.
Taro to Announce Results for Quarter Ended December 31, 2013
Business Wire - Mon Feb 03, 7:30AM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2013 after market close on Monday, February 10, 2014.
BlueMountain Capital Management and IsZo Capital To Update Shareholders Regarding Lawsuit Against Taro Pharmaceutical Industries, Call for the Resignation of External Directors
PR Newswire - Fri Jan 31, 6:04PM CST
BlueMountain Capital Management, LLC ("BlueMountain") and IsZo Capital LP ("IsZo"), two of the largest minority shareholders of Taro Pharmaceutical Industries Ltd. (NYSE: TARO; "Taro"), are today updating fellow shareholders regarding the status of their litigation against Taro and calling for the immediate resignation of Taro's illegitimately elected external directors.
Taro Schedules Extraordinary General Meeting for March 27, 2014
Business Wire - Thu Jan 23, 4:05PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that it has decided to schedule an extraordinary general meeting of shareholders (the "Meeting"), for March 27, 2014. The agenda for the Meeting will be the ratification of certain resolutions adopted by the Company's shareholders at its 2013 annual general meeting ("2013 AGM").
Annual J.P. Morgan Healthcare Conference Presentations, Results of Self-Tender Offer, and Executive Appointment - Research Report on ICU Medical, Integra, Taro, AMAG, and Array BioPharma
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
3 Health Care Stocks Wall Street Is Buying
George Budwell, The Motley Fool - Motley Fool - Tue Dec 31, 1:35PM CST
Playing follow the leader is often a good way to generate outsized returns in the market. But if you aren't sure why Wall Street is buying a certain stock, you may find yourself following them on their rare mistake. So with that in mind, here's my...
Taro Announces Final Results of Its Self-Tender Offer
Business Wire - Mon Dec 30, 6:15AM CST
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced the final results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013. Based on the final count by American Stock Transfer & Trust Company, LLC, the Depositary for the tender offer, an aggregate of 1,959,514 ordinary shares were properly tendered and not properly withdrawn at or below the final purchase price of $97.50 per share.
Taro Announces Preliminary Results of Its Self-Tender Offer
Business Wire - Tue Dec 24, 7:08AM CST
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013. Based on the preliminary count by American Stock Transfer & Trust Company, LLC ("AST"), the Depositary for the tender offer, approximately 1.96 million ordinary shares were properly tendered and not properly withdrawn at or below the expected final purchase price of $97.50 per share, including shares that were tendered through notices of guaranteed delivery.
NYSE stocks posting largest percentage increases
AP - Mon Nov 25, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
Taro Announces Commencement of Tender Offer to Repurchase up to $200 Million of Its Ordinary Shares
Business Wire - Mon Nov 25, 5:00AM CST
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it has commenced a modified "Dutch auction" tender offer to repurchase up to $200 million of its ordinary shares at a price not greater than $97.50 per share nor less than $84.50 per share (the "Offer"). If the Offer is fully subscribed, the number of shares to be purchased in the Offer represents approximately 4.6% to 5.3% of Taro's currently issued and outstanding shares depending on the purchase price payable for those shares pursuant to the Offer. The NYSE closing price of Taro ordinary shares on November 22, 2013, the last full trading day before today's announcement and commencement of this tender offer, was $89.57 per share.
BlueMountain Capital Management and IsZo Capital File Lawsuit Against Taro Pharmaceutical Industries Ltd. to Revoke the Results of the September 12, 2013 General Meeting
PR Newswire - Thu Nov 21, 4:04PM CST
BlueMountain Capital Management, LLC ("BlueMountain") informed its fellow minority shareholders today that BlueMountain, several of its funds, and IsZo Capital LP ("IsZo Capital") filed a claim against Taro Pharmaceutical Industries Ltd. (NYSE: TARO) on November 19, 2013 in the Israeli District Court for the Central District to vacate most of the resolutions which were voted upon at the general meeting of TARO's shareholders held on September 12, 2013 (the "General Meeting"). BlueMountain and IsZo Capital are the two largest minority shareholders of TARO.
Taro Provides Results for September 30, 2013
Business Wire - Tue Nov 12, 4:15PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three months and six months ended September 30, 2013.
NYSE stocks posting largest volume decreases
AP - Mon Nov 04, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
Taro to Announce Results for Quarter Ended September 30, 2013
Business Wire - Thu Oct 31, 3:23PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2013 after market close on Tuesday, November 12, 2013.
Caesarstone, Check Point Show Strong Fundamentals
at Investor's Business Daily - Fri Mar 07, 3:13PM CST
Although Chinese stocks have dominated this column in recent sessions, they are not the only game in town for investors looking to gain foreign exposure. A few Israeli firms also offer strong fundamentals and technicals. Caesarstone's (CSTE) top-line...
Ascending Bases Are Rare, But Can Spark Big Gains
at Investor's Business Daily - Fri Feb 21, 1:40PM CST
Sometimes, bullish technical setups aren't hard to see at all. A stock in an uptrend, for example, pauses to catch its breath, moves sideways for a bit and a flat base takes shape. Or a stock corrects 25% to 30% from its 52-week high, then starts to...
Taro Provides Results for December 31, 2013
Business Wire - Mon Feb 10, 4:05PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three months and nine months ended December 31, 2013.
Research and Markets: Agrochemicals and Pesticides Market in Iran: Business Report 2013
Business Wire - Tue Feb 04, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/h3sm5l/agrochemicals_and) has announced the addition of the "Agrochemicals and Pesticides Market in Iran: Business Report 2013" report to their offering.
Taro to Announce Results for Quarter Ended December 31, 2013
Business Wire - Mon Feb 03, 7:30AM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2013 after market close on Monday, February 10, 2014.
BlueMountain Capital Management and IsZo Capital To Update Shareholders Regarding Lawsuit Against Taro Pharmaceutical Industries, Call for the Resignation of External Directors
PR Newswire - Fri Jan 31, 6:04PM CST
BlueMountain Capital Management, LLC ("BlueMountain") and IsZo Capital LP ("IsZo"), two of the largest minority shareholders of Taro Pharmaceutical Industries Ltd. (NYSE: TARO; "Taro"), are today updating fellow shareholders regarding the status of their litigation against Taro and calling for the immediate resignation of Taro's illegitimately elected external directors.
Taro Schedules Extraordinary General Meeting for March 27, 2014
Business Wire - Thu Jan 23, 4:05PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that it has decided to schedule an extraordinary general meeting of shareholders (the "Meeting"), for March 27, 2014. The agenda for the Meeting will be the ratification of certain resolutions adopted by the Company's shareholders at its 2013 annual general meeting ("2013 AGM").
Annual J.P. Morgan Healthcare Conference Presentations, Results of Self-Tender Offer, and Executive Appointment - Research Report on ICU Medical, Integra, Taro, AMAG, and Array BioPharma
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
3 Health Care Stocks Wall Street Is Buying
George Budwell, The Motley Fool - Motley Fool - Tue Dec 31, 1:35PM CST
Playing follow the leader is often a good way to generate outsized returns in the market. But if you aren't sure why Wall Street is buying a certain stock, you may find yourself following them on their rare mistake. So with that in mind, here's my...
Taro Announces Final Results of Its Self-Tender Offer
Business Wire - Mon Dec 30, 6:15AM CST
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced the final results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013. Based on the final count by American Stock Transfer & Trust Company, LLC, the Depositary for the tender offer, an aggregate of 1,959,514 ordinary shares were properly tendered and not properly withdrawn at or below the final purchase price of $97.50 per share.
Taro Announces Preliminary Results of Its Self-Tender Offer
Business Wire - Tue Dec 24, 7:08AM CST
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013. Based on the preliminary count by American Stock Transfer & Trust Company, LLC ("AST"), the Depositary for the tender offer, approximately 1.96 million ordinary shares were properly tendered and not properly withdrawn at or below the expected final purchase price of $97.50 per share, including shares that were tendered through notices of guaranteed delivery.
NYSE stocks posting largest percentage increases
AP - Mon Nov 25, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
Taro Announces Commencement of Tender Offer to Repurchase up to $200 Million of Its Ordinary Shares
Business Wire - Mon Nov 25, 5:00AM CST
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it has commenced a modified "Dutch auction" tender offer to repurchase up to $200 million of its ordinary shares at a price not greater than $97.50 per share nor less than $84.50 per share (the "Offer"). If the Offer is fully subscribed, the number of shares to be purchased in the Offer represents approximately 4.6% to 5.3% of Taro's currently issued and outstanding shares depending on the purchase price payable for those shares pursuant to the Offer. The NYSE closing price of Taro ordinary shares on November 22, 2013, the last full trading day before today's announcement and commencement of this tender offer, was $89.57 per share.
BlueMountain Capital Management and IsZo Capital File Lawsuit Against Taro Pharmaceutical Industries Ltd. to Revoke the Results of the September 12, 2013 General Meeting
PR Newswire - Thu Nov 21, 4:04PM CST
BlueMountain Capital Management, LLC ("BlueMountain") informed its fellow minority shareholders today that BlueMountain, several of its funds, and IsZo Capital LP ("IsZo Capital") filed a claim against Taro Pharmaceutical Industries Ltd. (NYSE: TARO) on November 19, 2013 in the Israeli District Court for the Central District to vacate most of the resolutions which were voted upon at the general meeting of TARO's shareholders held on September 12, 2013 (the "General Meeting"). BlueMountain and IsZo Capital are the two largest minority shareholders of TARO.
Taro Provides Results for September 30, 2013
Business Wire - Tue Nov 12, 4:15PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three months and six months ended September 30, 2013.
NYSE stocks posting largest volume decreases
AP - Mon Nov 04, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
Taro to Announce Results for Quarter Ended September 30, 2013
Business Wire - Thu Oct 31, 3:23PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2013 after market close on Tuesday, November 12, 2013.
